Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

Journal of Infectious Diseases

Volumn 184, Issue 10, 2001, Pages 1331-1335

  McFarland, Elizabeth J ^a   Borkowsky, William ^b   Fenton, Terry ^e   Wara, Diane ^h   McNamara, James ^l   Samson, Pearl ^e   Kang, Minhee ^e   Mofenson, Lynne ^l   Cunningham, Coleen ^c   Duliege, Anne Marie ⁱ   Sinangil, Faruk ^i,q   Spector, Stephen A ^j   Jimenez, Eleanor ⁿ   Bryson, Yvonne ^k   Burchett, Sandra ^f   Frenkel, Lisa M ^g,o   Yogev, Ram ^p   Gigliotti, Francis ^d   Livingston, Robert A ^m,r  

^a UNIVERSITY OF COLORADO   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SYRACUSE UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m JOHNS HOPKINS UNIVERSITY   (United States)

ⁿ San Juan Veterans Hospital   (United States)

^o Landstuhl Regional Medical Center   (United States)

^p NORTHWESTERN UNIVERSITY   (United States)

^q VaxGen Inc   (United States)

^r ASTRAZENECA   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VERTICAL TRANSMISSION; WESTERN BLOTTING;

AIDS VACCINES; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; POLYSORBATES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SQUALENE; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 0035890181     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/323994     Document Type: Article

References (15)

1. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
2. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
3. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial
4. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF2 recombinant vaccines in uninfected volunteers
6. Immune responses to human immunodeficiency virus (HIV) type 1 reduced by canarypox expressing HIV-IMN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults
7. + cytotoxic T lymphocyte responses in seronegative volunteers
8. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
9. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in population at risk for acquired HIV type 1 infection
10. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120
11. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines
12. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-I) envelope vaccines in neonates born to HIV-1-infected women
13. Immunization of seronegative infants with hepatitis A vaccine (HAVRIX; SKB): A comparative study of two dosing schedules
14. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1 specific immune responses
15. Antigen-induced plaque-forming cell responses in cultures of peripheral blood mononuclear cells of human neonates and infants